Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.

  2. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

  3. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. … Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

    Categories: Agents Acting on the Renin-Angiotensin SystemProducts: TENCA I
  4. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    [A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and

  5. Drug

    Talarozole

    go.drugbank.com/drugs/DB13083
    Investigational

    Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

  6. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.

    Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTER
  7. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].

  8. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  9. Drug

    OBI-3424

    go.drugbank.com/drugs/DB16057
    Investigational

    OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL

    Synonyms: 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide, 3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide
  10. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. … It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.